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Abstract
Background: A considerable portion of the human genome derives from retroviruses inherited over millions of
years. Human endogenous retroviruses (HERVs) are usually severely mutated, yet some coding-competent HERVs
exist. The HERV-K(HML-2) group includes evolutionarily young proviruses that encode typical retroviral proteins.
HERV-K(HML-2) has been implicated in various human diseases because transcription is often upregulated and
some of its encoded proteins are known to affect cell biology. HERV-K(HML-2) Protease (Pro) has received little
attention so far, although it is expressed in some disease contexts and other retroviral proteases are known to
process cellular proteins.
Results: We set out to identify human cellular proteins that are substrates of HERV-K(HML-2) Pro employing a
modified Terminal Amine Isotopic Labeling of Substrates (TAILS) procedure. Thousands of human proteins were
identified by this assay as significantly processed by HERV-K(HML-2) Pro at both acidic and neutral pH. We
confirmed cleavage of a majority of selected human proteins in vitro and in co-expression experiments in vivo.
Sizes of processing products observed for some of the tested proteins coincided with product sizes predicted by
TAILS. Processed proteins locate to various cellular compartments and participate in diverse, often disease-relevant
cellular processes. A limited number of HERV-K(HML-2) reference and non-reference loci appears capable of
encoding active Pro.
Conclusions: Our findings from an approach combining TAILS with experimental verification of candidate proteins
in vitro and in cultured cells suggest that hundreds of cellular proteins are potential substrates of HERV-K(HML-2)
Pro. It is therefore conceivable that even low-level expression of HERV-K(HML-2) Pro affects levels of a diverse array
of proteins and thus has a functional impact on cell biology and possible relevance for human diseases. Further
studies are indicated to elucidate effects of HERV-K(HML-2) Pro expression regarding human substrate proteins, cell
biology, and disease. The latter also calls for studies on expression of specific HERV-K(HML-2) loci capable of
encoding active Pro. Endogenous retrovirus-encoded Pro activity may also be relevant for disease development in
species other than human.
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Background
Human endogenous retroviruses (HERVs), originating
from past infections by exogenous retroviruses, and de-
rived elements with some retroviral features, comprise
about 8% of the human genome. HERVs affect the biol-
ogy of the human genome in various ways, ranging from
influences on transcription and splicing to biological ef-
fects of retrovirus-like proteins still encoded by some
HERV groups. For instance, the envelope glycoprotein
encoded by a provirus of the so-called HERV-W group
was coopted to form the ERVW-1 (Syncytin-1) gene,
whose protein product exerts important functions in hu-
man placenta development and functionality [1]. The
HERV-K(HML-2) group, in short HML-2, includes a
number of evolutionarily young proviruses, several of
which are human-specific or even polymorphic in the
human population [2]. Transcription of some HML-2
loci is upregulated in various human diseases with po-
tential consequences due to the interaction of HML-2-
encoded proteins with other cellular proteins (for re-
views, see [3–5]). For instance, certain types of testicular
and ovarian germ cell tumors (GCTs), as well as melan-
oma and mammary carcinomas, display upregulated
HML-2 transcription (reviewed in [6, 7]). Upregulated
HML-2 transcription could be observed in lesions con-
sidered precursors of testicular GCTs, so-called carcin-
oma in situ of the testis [8]. GCT patients suffering from
GCT-types with HML-2 upregulation already show a
strong humoral response against HML-2-encoded Gag
and Env proteins at the time of tumor detection [9, 10].
HML-2 encoded Env protein was recently shown to in-
duce several transcription factors and to activate the cel-
lular transformation-associated MAPK ERK1/2 pathway
[11]. HML-2 Rec and Np9 proteins, encoded by spliced
transcripts from the HML-2 env gene, were shown to
interact with several human proteins, among them pro-
myelocytic zinc finger protein (PLZF), testicular zinc fin-
ger protein (TZFP), Staufen-1, human small glutamine-
rich (hSGT), and ligand of Numb protein X (LNX). Rec
expression disturbed germ cell development in mice and
altered testis histology towards a carcinoma-like pheno-
type [12–18].
Retroviral genomes usually encode several catalytic
proteins, among them aspartyl Protease (Pro). HML-2
also encodes Pro that, after self-processing from a Gag-
Pro(−Pol) precursor translated through ribosomal frame-
shifts, cleaves retroviral HML-2 Gag protein into matrix,
capsid and nucleocapsid domains, as is typical for other
retroviral aspartyl proteases [19–21]. There is strong evi-
dence that active HML-2 Pro is expressed at significant
amounts and during longer periods of time, especially
for GCT. HML-2-encoded retroviral particles budding
from GCT cell lines have been detected. Large amounts
of HML-2 Gag protein are present in GCT tissue and
HML-2 Pro-cleaved Gag protein was demonstrated in
GCT cell lines and especially tissue samples [10, 22].
Bieda et al. [23] demonstrated mature HML-2-encoded
retroviral particles budding from different GCT cell
lines, immature non-budding retroviral particles, as well
as cleaved Gag protein in those cell lines. Prokaryotic ex-
pression of a construct harboring HML-2 Gag-Pro ORFs
results in self-processing of Pro from a Gag-Pro precur-
sor [24], thus Pro is capable of self-processing independ-
ent of retroviral particle formation and budding.
Besides retroviral Gag protein, retroviral aspartyl pro-
teases were found to cleave host cellular proteins. HIV
Pro processes human Actin, Troponin C, Alzheimer
amyloid precursor protein, and Pro-interleukin 1β in
vivo. Purified HIV Pro processes Vimentin, Desmosin,
and Glial fibrillary acidic protein, and Microtuble-associ-
ated proteins 1 and 2 in vitro (reviewed in [25]). Riviere
et al. [26] reported processing of the precursor of NF-
kappa B by HIV-1 Pro during acute infection. Processing
of Vimentin by proteases of Bovine Leukemia Virus,
Mason–Pfizer Monkey Virus, and Myeloblastosis-Asso-
ciated Virus was reported by Snásel et al. [27]. Shoeman
et al. [28] reported cleavage of focal adhesion plaque
proteins, including Fimbrin, Focal adhesion plaque kin-
ase, Talin, Filamin, Spectrin and Fibronectin by HIV-1
and HIV-2 proteases. Devroe at al. [29] reported pro-
cessing of human NDR1 and NDR2 serine-threonine ki-
nases by HIV-1 Pro. More recently, more than 120
cellular substrates were reported to be processed by
HIV-1 Pro in vitro by Impens et al. [30]. Thus, aspartyl
proteases from diverse retroviruses appear able to de-
grade quite a number of host cellular proteins. Further-
more, such processing of cellular proteins by retroviral
Pro can occur independent of retroviral budding. For in-
stance, cleavage of procaspase 8 by HIV-1 Pro was ob-
served during HIV-1 infection of T-cells and other cell
types [31, 32]. HIV-1 Pro was reported to cleave serine-
threonine kinases RIPK1 and RIPK2 during HIV-1 infec-
tion of T-cell lines or primary activated CD4+ T cells
([33], see references therein for additional examples). A
significant amount of processing of HIV-1 Gag occurs in
the cytoplasm of infected cells resulting in intracellular
accumulation of appropriately processed HIV-1 Gag
proteins [34]. For Mouse Mammary Tumor Virus
(MMTV), a betaretrovirus closely related with HERV-
K(HML-2), activation of Pro can occur before budding,
and MMTV Gag protein is primarily found in the cyto-
plasm and traffics to intracellular membranes to initiate
particle assembly. Similar observations were made for
Human Foamy Virus [35–37]. Thus, retroviral Pro pro-
teins are activated not only during maturation of retro-
viral particles.
There is evidence that such processing of cellular pro-
teins by retroviral Pro is of biological relevance. Strack
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et al. [38] reported that apoptosis of HIV-infected cells
was preceded by HIV Pro-mediated cleavage of Bcl-2.
Cleavage of Procaspase 8 by HIV Pro in T-cells was
followed by cellular events characteristic of apoptosis
[31]. HIV Pro inducibly expressed in yeast caused cell
lysis due to alterations in membrane permeability. Cell
killing and lysis, specifically lysis by necrosis without
signs of apoptosis, was observed in COS-7 cells follow-
ing expression of HIV Pro [39]. Cleavage of EIF4G by
several retroviral proteases profoundly inhibited cap-
dependent translation [40]. Specific inhibition of HIV
Pro reduced the extent of both necrosis and apoptosis in
C8166 cells [41]. It was recently proposed that cleavage
of RIPK1 by HIV-1 Pro might be one of several mecha-
nisms by which HIV-1 counteracts host innate immune
responses [33].
There is thus good evidence for cellular effects follow-
ing expression of retroviral Protease. Although retroviral
Protease is encoded in the human genome by HERV-
K(HML-2) and expressed in the disease context, there is
surprisingly little information as to potential functional
relevance of HML-2 Pro expression. We therefore set
out to identify human proteins processed by HML-2 Pro
by employing specialized proteomics methods. Numer-
ous human proteins were identified as substrates of
HML-2 Pro. We further verified processing by HML-2
Pro for selected proteins in vitro and in vivo. Human
proteins identified often exert various, often important
cellular functions, and many of them are disease-rele-
vant. The relevance of our findings for human disease is
currently unknown, yet the sheer number of potentially
disease-relevant proteins identified in our study as po-
tential substrates of HML-2 Pro strongly argues for fur-
ther specific analyses.
Results
Optimization of HERV-K(HML-2) protease activity
We sought to identify human cellular proteins that are
substrates of HERV-K(HML-2) Pro, employing a modified
Terminal Amine Isotopic Labeling of Substrates (TAILS)
protocol [42, 43]. We first optimized HERV-K(HML-2)
Protease activity prior to TAILS. We employed a cloned
HML-2 Pro previously identified and shown to be enzy-
matically active [24]. Of note, the cloned Pro included
self-processing sites and in-frame flanking sequence.
HML-2 Pro was prokaryotically expressed and subse-
quently purified using a previously published protocol
employing Pepstatin A, a specific inhibitor of retroviral as-
partate proteinases, coupled to agarose beads [44]. In ac-
cordance with previous results, HML-2 Pro could be
purified very efficiently and at relatively high yields (Fig. 1).
As also observed before [44], HML-2 Pro self-processed
from the precursor during the expression, purification,
and renaturation steps (Additional file 2: Figure S1). We
note that two different, enzymatically inactive mutants of
HML-2 Pro (harboring mutations in catalytic motifs, see
the Methods section) could not be purified due to ineffi-
cient binding to Pepstatin A-agarose (Additional file 2:
Figure S1).
Previous studies of HML-2 and other retroviral Prote-
ases employed differing buffer systems and pH condi-
tions when measuring HML-2 Pro activity (for instance,
see [44, 45]). We therefore determined HML-2 Pro ac-
tivity in various buffer systems using a fluorescent sub-
strate previously shown to be processed by HIV Pro [46]
and expected also to be processed by HML-2 Pro be-
cause of its very similar specificity profiles [47]. We
found that HML-2 Pro displayed higher activity at con-
ditions of high ionic strength. Higher concentrations of
glycerol appeared to reduce HML-2 Pro activity (see the
legend to Fig. 2), as did DMSO of 2% [v/v] and higher
(not shown). Of further note, very similar HML-2 Pro
activity was observed at different pH conditions for MES
and PIPES-based buffer systems (not shown). A buffer
composed of 100 mM MES and 1M NaCl was chosen
for lysis of HeLa cells and a PIPES-based buffer system
was used for TAILS (see below). Further variation of re-
action conditions between pH 5.5 and 8 established that
HML-2 Pro was most active at pH 5.5 and somewhat
less active at pH 6. Further reduced activity was seen for
pH > 6, yet HML-2 Pro still displayed low activity at pH
8 (Fig. 2). In principle, these results are generally in
Fig. 1 Purification of HERV-K(HML-2) Protease. A previously
established method for purification of prokaryotically expressed
HML-2 Pro was employed with minor modifications (see text).
Samples were taken at various steps of the procedure, such as
bacterial culture before induction (“pre-ind.”), flow-through (“flow-
thr.”) after binding of bacterial lysate to Pepstatin A-agarose, two
wash fractions, and 4 elution fractions. Proteins were separated by
SDS-PAGE in a 15% PAA-gel and visualized by staining with
Coomassie Blue. Molecular mass of marker proteins (M) are indicated
on the left. Purified, auto-processed HML-2 Pro migrates at
approximately 12 kDa
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accord with previous findings (for instance, see [20]). As
further addressed below, several cellular compartments
have an acidic pH of 6 or less [48].
Subsequent TAILS experiments involved Pepstatin A as
an inhibitor of HML-2 Pro activity. We therefore also
established the molar ratio required to effectively inhibit
HML-2 Pro. We found that 200 μM Pepstatin A efficiently
inhibited HML-2 Pro present at 460 nM. Inhibition was
even more pronounced when reactions were pre-incubated
with Pepstatin A for 10min before addition of fluorescent
substrate (Fig. 2).
Identification of numerous human cellular proteins
cleaved by HERV-K(HML-2) protease using TAILS
Previous studies indicated that retroviral aspartate Prote-
ases, including HIV Pro, can process not only retrovirus-
encoded proteins but also cellular proteins (see the
Background section). We therefore were interested
whether HML-2 Protease is also able to process human
cellular proteins other than HML-2-encoded Gag pro-
tein. To do so, we employed a modified Terminal Amine
Isotopic Labeling of Substrates (TAILS) procedure that
identifies Protease-cleaved protein fragments by means
of specific labeling and subsequent isolation of processed
amine termini followed by mass-spectrometry [42, 43].
We incubated HeLa cell total protein lysate with purified
HML-2 Pro employing established reaction conditions
with regard to salt concentration, pH, and molar ratio of
Protease and Pepstatin A (see above). HML-2 Pro-gener-
ated cleavage sites were subsequently identified by N-
terminomics [43] using the TAILS approach. As a nega-
tive selection technique, TAILS is suitable for the ana-
lysis of natively blocked (e.g. acetylated) and natively free
N-termini. Since proteolysis generates free N-termini,
we focused on these species. During the TAILS proced-
ure, free N-termini are chemically dimethylated.
We performed TAILS experiments at pH 5.5 and pH
7. As for the experiment at pH 5.5, TAILS identified
Fig. 2 Optimization of reaction conditions of HERV-K(HML-2)
Protease. Purified HML-2 Pro was incubated with a fluorescent
anthranilyl-substrate and fluorescence emission was measured for
the indicated time periods. Influence of different buffer
compositions (top), pH values (middle), and Pepstatin A
concentrations (bottom) on HML-2 Pro activity are depicted. Buffer
compositions were as follows: Buffer 1: 20 mM PIPES, 100 mM NaCl,
1 mM DTT, 10% [v/v] Glycerol, pH 6.5; Buffer 2: 50 mM MES, 1 M NaCl,
20% [v/v] Glycerol, 1 mM EDTA, pH 5.0; Buffer 3: 50 mM MES, 1 M
NaCl, 1 mM EDTA, pH 5.0; Buffer 4: 100 mM MES-TRIS, 1.25 M NaCl,
pH 6.0. Effects of pH were measured in a buffer consisting of 100
mM MES, 1 M NaCl. Note the differing glycerol concentrations of
buffers 2 and 3 (see the text). Also note that reactions at pH 5.5 and
pH 6 depleted the substrate after approximately 110 min due to
high HML-2 Pro activity. Effects of Pepstatin A at 200 μM were
measured with and without pre-incubation of protease with
Pepstatin A
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greater than 8500 native free or proteolytically generated
N-termini in both replicates 1 and 2 (Fig. 3,
Additional file 1: Tables S1a,b). As an initial filter to dis-
cern background proteolysis from HML-2 Pro-
dependent cleavage events, we selected those cleavage
events that were enriched at least 2-fold upon HML-2
Pro incubation. We observed 4370 cleavage events in
replicate 1 and 2633 cleavage events in replicate 2. A
variation in protease activity, as well as the different
methodological processing steps, may contribute to this
variance. Of those, 931 cleavage events were common to
both replicates (Fig. 3, Additional file 1: Tables S1a,b)
and those corresponded to 548 different human pro-
teins. For proteins cleaved in both replicates with at least
2-fold enrichment, yet not necessarily cleaved in the
same position within a protein, we identified 2024 and
1170 unique protein IDs in the two replicates, respect-
ively. Combining both replicates, 809 different human
proteins showed replicated evidence of cleavage by
HML-2 Pro (Fig. 3b, Additional file 1: Tables S1a,b). As
implied by the above numbers, several human proteins
showed multiple cleavage events per protein (Fig. 3c).
For instance, we observed for Heat Shock Protein 90
Alpha Family Class B Member 1 (HSP90AB1) 30 and 50
cleavage events with at least 2-fold enrichment in differ-
ent positions of the protein in replicates 1 and 2, re-
spectively. For Myosin Heavy Chain 9 (MYH9), 25 and
60 cleavage events were observed, for Actin Beta
(ACTB) 38 and 32, and for Heat Shock Protein Family A
(Hsp70) Member 8 (HSPA8) 11 and 36, respectively
(Additional file 1: Table S2).
Since protein degradation by HML-2 Pro may also
occur in the cytoplasm or nucleoplasm at neutral pH ra-
ther than in acidic organelles, we also performed a TAILS
experiment at pH 7. Overall, we observed fewer cleavage
events, possibly due to lower enzymatic activity of HML-2
Pro at pH 7 (Fig.3a, Additional file 1: Tables S1c,d). Never-
theless, greater than 3100 native free or proteolytically
cleaved N-termini were identified for replicates 1 and 2,
respectively, of which 1074 (replicate 1) and 514 (replicate
2) cleavage events were enriched greater than 1.5-fold
upon HML-2 Pro incubation, with an overlap of 58 cleav-
age events. For the pH 7.0 assay, we chose a less stringent
cutoff value of 1.5-fold-change due to the lower activity of
HML-2 Pro at pH 7.0. For a lower protease activity the
TAILS approach may miss more potential substrates at
the more stringent cutoff value of 2. Though, at the lower
cutoff value the potential candidates have to be considered
more carefully and additional experiments like the in vitro
experiments and the experiments with cultured cells are
of greater value. At a cutoff value of 1.5-fold-change, 442
(replicate 1) and 369 (replicate 2) different human pro-
teins were affected by HML-2 Pro incubation. Combining
the latter experiments, a total of 154 different human
proteins showed replicated evidence of cleavage by HML-
2 Pro at pH 7 (Fig. 3b). Of note, four human proteins were
identified only in the pH 7 TAILS experiment, though
with relatively low to medium enrichment of processing
products (TAGLN: 3.8-fold; MAP1B: 4.1-fold; KTN1: 1.7-
fold; EPB41L2: 1.6-fold).
Similar to the TAILS experiment at pH 5.5, we ob-
served at pH 7 multiple cleavage events within several of
human proteins enriched greater than 1.5-fold. For in-
stance, there were 25 and 15 cleavage events in repli-
cates 1 and 2, respectively, for HSP90AB1, 41 and 6
events for MYH6, 17 and 3 for ACTB, and 40 and 7
events for HSPA8 (Fig. 3c, Additional file 1: Table S2).
Combining all results, we identified 102 different human
proteins cleaved by HML-2 Pro that were detected in all
four TAILS experiments when applying 2-fold enrichment
at pH 5.5 and 1.5-fold enrichment at pH 7 (Fig. 3b). We
consider these findings to bear evidence of possible pro-
cessing of human proteins by HML-2 Pro.
Involvement of human proteins cleaved by HML-2
protease in diverse cellular processes
We next used the Gene Ontology (GO) database [49, 50]
to identify biological properties of proteins identified by
TAILS. Analysis of the 809 different human proteins com-
mon to the two pH 5.5 experiments indicated localization
of proteins in diverse cellular compartments including
cytosol, nucleus and membrane (Fig. 4a). Further GO
term-based analysis of biological processes associated with
the 809 human proteins showed their involvement in nu-
merous biological processes, e.g. apoptosis, cell cycle regu-
lation, DNA repair and replication, ion and nuclear
transport (Fig. 4b). Moreover, intersection of the human
genes corresponding to those 809 human proteins with
genes included in the Catalogue Of Somatic Mutations In
Cancer (COSMIC) database [53] identified 62 human
genes/proteins in our dataset with an established rele-
vance in oncology (Fig. 4b, Additional file 1: Table S3).
Querying the Online Mendelian Inheritance in Man
(OMIM) database [54] revealed genes for our dataset of
809 proteins to be associated with 265 different genetic
disorder phenotypes, of which approximately 239 were de-
scribed as inherited (Additional file 1: Table S4).
Verification of cleavage of human proteins by HERV-
K(HML-2) protease in vitro
We next sought to verify in vitro cleavage by HML-2
Pro of proteins identified by TAILS experiments. We fo-
cused on substrate candidates that were enriched more
than 2-fold upon active HML-2 incubation in both repli-
cates of the TAILS experiment at pH 5.5. A recent study
profiled amino acid specificities of HERV-K(HML-2) Pro
at aa positions P6–P1 and P1’–P6’ in, respectively, N-
terminal and C-terminal direction with respect to the
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Fig. 3 (See legend on next page.)
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cleaved bond revealing, for instance, P1 as the major de-
terminant of specificity and a preference for aromatic aa
residues in P1 [47]. A subsequent profiling at pH 7 like-
wise revealed preferences for aromatic aa residues in P1
and aromatic and aliphatic aa residues in P1’ (data not
shown). We utilized these published findings to reduce
the list of candidate proteins by filtering for peptides
from cleavage events having F, G, Y or W in P1, and F,
I, L, V or W in P1’ (Fig. 3a). Furthermore, we selected
proteins with a size compatible with an in vitro coupled
transcription/translation system, and cellular localiza-
tions and biological functions based on associated GO
terms. Eventually, we further analyzed 14 different hu-
man proteins (Table 1).
We produced candidate proteins in vitro in a coupled
transcription/translation system using either a radio-
active label (35S-methionine) or a C-terminal HA-tag.
We then incubated equal amounts of each candidate
protein with purified HML-2 Pro, including a control re-
action without Pro and one with Pro enzymatic activity
inhibited by presence of Pepstatin A. Reactions were
then subjected to SDS-PAGE followed by phosphorima-
ger or Western blot analysis depending on the protein
label.
Fig. 4 Gene Ontology term-based characteristics of human proteins identified as substrates of HERV-K(HML-2) Protease by TAILS. Selected cellular
components (a) and biological processes (b) are depicted. Numbers were compiled using PANTHER (Protein ANalysis THrough Evolutionary
Relationships) GO-Slim as provided at http://geneontology.org [51, 52]. Numbers of proteins per category expected by chance are also given.
Graph (b) also depicts in the bottom-most bar the overlap of proteins identified by TAILS with cancer-relevant genes as compiled by COSMIC
(Catalogue Of Somatic Mutations In Cancer; https://cancer.sanger.ac.uk/cosmic) [53]. See Additional file 1: Table S3 for COSMIC cancer genes
(See figure on previous page.)
Fig. 3 Cleavage sites in human proteins identified as substrates of HERV-K(HML-2) Protease by TAILS. a. Results of filtering of cleavage sites
observed by TAILS. Results for two experiments (rep1, rep2) performed at pH 5.5 and pH 7 are each depicted. Various filters were applied, such as
greater than 1.5-fold or 2-fold (fc) enrichment for the observed cleavage event compared to controls and particular amino acids in P1 and P1’
(see the paper text). Resulting numbers after applying the various filters are indicated by bars and by specific numbers when including P1 and
P1’. b. Venn diagrams depicting overlap of cleavage sites and protein IDs in replicates (rep1, rep2) performed at pH 5.5 and pH 7. The overlap of
protein IDs detected in all four experiments is depicted in the Venn diagram at the bottom. c. Numbers of cleavage sites in proteins identified as
substrates of HERV-K(HML-2) Pro. Results are summarized for the replicate (rep1, rep2) TAILS experiments at pH 5.5 and pH 7. A single cleavage
event was observed for the vast majority of proteins, fewer proteins were cleaved at more than one position, and a relatively small number of
proteins were cleaved at up to 60 different positions within the particular protein. See Additional file 1: Table S2, for selected human proteins
with multiple cleavage sites
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Out of 14 different human proteins examined, we ob-
tained evidence for processing by HML-2 Pro in vitro
for 9 of those proteins. Evidence for processing included
(i) a more or less reduced amount of full-length candi-
date protein compared to amounts of full-length protein
in control reactions without Pro and with Pro plus Pep-
statin A, (ii) presence of one or several additional pro-
tein bands in the reaction with Pro compared to the
reaction without Pro, (iii) such additional protein bands
also being present in the reaction with Pro plus Pepsta-
tin A, yet at (much) lower amounts compared to the re-
action with Pro. Different combinations of those criteria
were observed in our verification experiments. In con-
trast, no or inconclusive evidence for processing by
HML-2 Pro was obtained for 5 human proteins tested
(Fig. 5a and Additional file 2: Figure S2).
TAILS experiments also provided information for ac-
tual cleavage site positions in candidate proteins. We
found for 6 of the 14 different human proteins tested
that HML-2 Pro had produced additional protein bands
coinciding with sizes of processing products predicted
by cleavage sites identified by TAILS (Fig. 5b).
Verification of cleavage of human proteins by HERV-
K(HML-2) protease in vivo
We also investigated candidate proteins for their ability
to be processed in vivo. We selected proteins confirmed
in vitro as substrates of HML-2 Pro, along with proteins
identified by TAILS that were of functional interest and
readily available to us as cloned cDNAs. We co-
expressed in HEK293T cells epitope-tagged candidate
proteins together with wild-type (enzymatically active)
or mutant (inactive) HML-2 Pro, with or without an en-
hanced green fluorescent protein (EGFP) tag, and per-
formed Western blot analysis with epitope-tag-specific
antibodies. Expression of Pro was detected using either a
polyclonal α-HML-2 Pro antibody [19], or an α-EGFP
antibody (kindly provided by Gabriel Schlenstedt, Uni-
versity of Saarland). The α-Pro pAb detected proteins of
sizes expected for self-processed and (unprocessed) pre-
cursor forms of both wild-type and mutant HML-2 Pro.
The α-EGFP antibody detected proteins of sizes ex-
pected for EGFP-Pro precursor and the EGFP portion
after auto-processing of Pro (Fig. 6a). Importantly, pro-
cessing of HML-2 Pro from an EGFP-Pro fusion protein
provides further strong experimental support for HML-2
Pro becoming active independent of retroviral particle
formation and budding.
For many of the tested candidate proteins, we ob-
served pronounced reduction of the amount of full-
length candidate protein, in some instances to below de-
tection limits (Fig. 6a, b and Additional file 2: Figure S3).
Notably, for some of the tested candidate proteins, add-
itional products smaller in size than the full-length
proteins were detected when co-expressing wild-type
but not mutant HML-2 Pro, specifically for C15orf57-
HA, HSP90-HA, MAP2K2-HA, FLAG-TRIM28, FLAG-
RNASEH2A, and Myc-STUB1 (Fig. 6a, b). For three pro-
teins, sizes of such additional products were very similar
to sizes of cleaved protein products detected in the in
vitro verification experiments. Specifically, a fragment of
15 kDa was seen for C15orf57-HA. A fragment of 60
kDa was also detected for HSP90 by both the anti-HA
and the anti-HSP90 antibodies. The latter antibody also
detected an approximately 50 kDa fragment of HSP90. A
fragment of approximately 42 kDa was also detected for
MAP2K2-HA (compare Figs. 5a, 6a, b). This suggests
that HML-2 Pro processing of these candidate proteins
in vivo reproduced the same (more or less stable) pro-
cessing products as the in vitro reactions. Truncated
protein products were also detected by Western blotting
of additional candidate proteins tested only in vivo, spe-
cifically 62 kDa, 30 kDa, and 31 kDa bands for FLAG-
TRIM28, FLAG-RNASEH2A, and Myc-STUB1, respect-
ively (Fig. 6b). Thus HML-2 Pro-mediated processing of
these proteins also appears to produce stable processing
products.
Importantly, and similar to the in vitro verification ex-
periments, the sizes of additional protein products ob-
served coincided well with the sizes predicted by
cleavage sites identified in TAILS experiments (Fig. 6c).
Degradation of candidate proteins is not due to HML-2
protease induced cell death
When expressing HML-2 Pro in HEK293T and HeLa
cells, we noted under the microscope cell death for a
relatively small proportion of cells. The amount of cell
death seemed higher for HeLa than for HEK293T cells.
No such cell death was observed when expressing mu-
tant HML-2 Pro. Cell death appeared reduced in the
presence of 1 μM indinavir, a strong inhibitor of HIV
Pro, and with less potency against HML-2 Pro in cell
culture (not shown) [20, 56].
We therefore quantified by FACS analysis the relative
amount of cell death following HML-2 EGFP-Pro expres-
sion in HEK293T cells. We determined relative numbers
of EGFP-, thus Pro-expressing cells at 5, 10, 24, 30, and
48 h after transient transfection with plasmids encoding
either EGFP, EGFP-Pro-wt, or EGFP-Pro-mut. Approxi-
mately 60% of gated live cells expressing EGFP-Pro-wt or
EGFP-Pro-mut were EGFP-positive up to 48 h post-trans-
fection, indicating that only a minority of cells expressing
HML-2 Pro are driven into cell death over the course of
our expression experiments (Additional file 2: Figure S4).
HIV Pro has also been reported to induce apoptosis
(see the Background section). Various cellular proteins
are degraded during apoptosis due to activation of cas-
pases [57]. We therefore asked whether observed cleavage
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of candidate proteins by HML-2 Pro could also be attrib-
uted to cleavage by caspases. We transiently expressed
proteins HSPA90AA1-HA, MAP2K2-HA and C15orf57-
HA in HEK293T cells and subsequently induced apoptosis
by addition of Staurosporin at 2 μM. HEK293T cells har-
vested after 5 h did not show evidence of processing of
Fig. 5 Verification of processing of human proteins by HERV-K(HML-2) Protease in vitro. Human candidate proteins were expressed in vitro using
a coupled transcription/translation system. a. Results from protease incubations of various candidate proteins labeled with either 35S-methionine
or a C-terminal HA-tag (“35S” and “HA”) are shown. Experiments included for each candidate protein a reaction without protease (“C”), one with
protease (“+”), and one with protease and Pepstatin A (“+/P”). Reaction products were separated by SDS-PAGE in 10% PAA-gels and processed for
phosphorimager analysis or HA-tag-specific Western blots depending on the label. Processing of full-length candidate proteins (indicated by an
arrow) was evidenced by additional protein bands smaller than the respective full-length candidate protein (arrowheads) and/or a decrease in
the amount of full-length candidate protein (see the Results section). One example of a candidate protein (PSMC4) without evidence of
processing by HML-2 Pro is shown. b. Graphical depiction of candidate proteins confirmed to be processed by HML-2 Pro. The number of amino
acids and corresponding molecular mass in kDa is indicated by scales at the top and by the line length for each protein. Positions of methionines
and cleavage sites (grey and black arrowheads, respectively), as identified by TAILS in either one of the two replicate experiments at pH 5.5 (see
the text), are indicated for each protein. Dashed lines indicate molecular masses of processing products observed experimentally for either 35S-
methionine (“35S”)- or HA-tag (“HA”)-labeled candidate proteins. Note that the latter label will only detect C-terminal processing products.
Processing products were not indicated for the two HSP90A proteins because observed products were difficult to assign due to too many
observed cleavage sites. Processing of PDIA3 protein was supported by reduction of the amount of full-length protein, though no smaller
processing products could be observed. Note that C15orf57 migrated slower in gel electrophoresis than predicted by molecular mass. See
Additional file 2: Figure S2 for additional evidence of processing of candidate proteins by HML-2 Pro
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Fig. 6 (See legend on next page.)
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candidate proteins due to apoptotic processes (Additional
file 2: Figure S4). Importantly, a processing product of a
size observed when co-expressed with HML-2 Pro was
not visible (Fig. 6a, b). Of further note, in the case of
HSP90AA1-HA and MAP2K2-HA co-expressed with
HML-2 Pro, addition of a pan-caspase inhibitor (Q-VD,
25 μM) did not reduce the amount of processing product
observed, but rather increased it slightly when compared
to control cells expressing HML-2 Pro in the absence of
Q-VD (Additional file 2: Figure S4).
Several HERV-K(HML-2) loci in the human genome
potentially encode active protease
We were interested in which HML-2 loci in the human
genome may produce an active Protease when they are
transcribed and translated in a retroviral fashion, that is, the
Pro ORF is translated via ribosomal frameshift between the
Gag and Pro ORFs. Therefore, we examined HML-2 locus
sequences in the human reference genome sequence, as
well as among HML-2 sequences previously reported as
missing from the reference genome, for presence of Gag
and Pro ORFs. We subsequently predicted sequences of
encoded Pro proteins for HML-2 loci fulfilling those criteria
(Fig. 7). We identified 6 different HML-2 loci in the human
reference genome (3q27.2_ERVK-11; 5q33.3_ERVK-10;
6q14.1_ERVK-9; 7p22.1_ERVK-6; 8p23.1_ERVK-8 (K115);
12q14.1_ERVK-21) potentially capable of translating a Pro
protein of canonical length. None of the corresponding
protein sequences displayed amino acid alterations within
the conserved catalytic DTG, FLAP and GRDLL motifs
(Fig. 7). Of note, HML-2 locus 3q27.2_ERVK-11 displayed
a fused Gag-Pro ORF extending approximately 700 aa in
the N-terminal direction. Another HML-2 locus
(22q11.21_ERVK-24) displayed a premature stop codon in
the conserved GRDLL motif. Three out of four non-refer-
ence HML-2 sequences displayed full-length ORFs, yet one
of them harbored a G→ S change and another an I→V
change within the FLAP-motif (Fig. 7).
Discussion
Retroviral aspartyl proteases are known to process
various cellular proteins that are not directly corre-
lated with or important for the retroviral replication
cycle. Processing of such cellular proteins does not
appear to play a major role during replication of ex-
ogenous retroviruses and may be regarded rather as
cellular side effects of infections by exogenous retrovi-
ruses. However, processing of cellular proteins by
retroviral proteases may be much more critical when
the protease is encoded by endogenous retroviruses
that are stable, vertically inherited components of a
genome. In fact, the HERV-K(HML-2) group encodes
active protease and HML-2 transcription and expres-
sion of HML-2 proteins has been reported to be up-
regulated in various human cancers, sometimes early
in cancer development, such as in GCT carcinoma in
situ [8]. Importantly, there is strong evidence that active
HML-2 Pro is expressed in tumor cells and tumor-derived
cell lines. HML-2 encoded retroviral particles budding
from GCT cell lines were shown 25 years ago (for in-
stance, see [22]). Large amounts of processed HML-2 Gag
protein are present in GCT tissue and processed HML-2
(See figure on previous page.)
Fig. 6 Verification of processing of human proteins by HERV-K(HML-2) Protease in vivo. Human candidate proteins and HML-2 Pro were co-
expressed in HeLa cells in vivo and detected by Western blot using antibodies as indicated. For each blot, the leftmost lane is a control co-
transfected with a plasmid encoding a candidate protein and either a GFP-encoding plasmid or empty phCMV, pcDNA6 myc/his B, or pcDNA5
FRT/TO vector, depending on GFP-Pro or (sole) Pro co-expressed in the experiment (see below). Candidate protein co-expressed with wild-type
Pro (pro-wt) and mutant Pro (pro-mut) were loaded in lanes 2 and 3 each. Pro was expessed as either (sole) Pro or EGFP-Pro. Blots were probed
with α-HA, α-GFP, α-Pro, or an α-HSP90 antibody as indicated. Full-length candidate protein and processing products are indicated by arrows and
arrowheads, respectively (see below). A Representative results from control experiments co-expressing HSP90AA1 with either HML-2 Pro or EGFP-
Pro. Relevant blot regions are shown. When expressing pro-wt and pro-mut, HML-2 Pro can be detected as approximately 18 kDa and 19 kDa
protein bands representing self-processed and unprocessed products, respectively, Pro (a, bottom blot). When HML-2 Pro is expressed as EGFP-
Pro-wt or EGFP-Pro-mut fusion protein, proteins of approximately 30 kDa and 47 kDa, representing processed and unprocessed EGFP(−Pro) can
be detected with an α-GFP antibody (b, middle blot). Unprocessed EGFP-Pro(−mut) and self-processed Pro of approximately 50 kDa and 18 kDa,
respectively, can be detected when using an α-Pro antibody (b, bottom blot; c). B. Selected Western blot results from co-expression of candidate
proteins and HML-2 Pro. Candidate proteins were tagged with N- or C-terminal epitopes and detected with respective epitope-specific antibodies
as indicated. Note the more or less complete reduction of amounts of full-length candidate protein (arrows), and sometimes processing products
(arrow heads), in lanes with co-expressed HML-2 Pro. Note in panel Aa and Ab that the same processing product was detected for HSP90AA1 in
vitro and in vivo (the HSP90AA1 in vitro result is shown again in Ad for the sake of convenience). Also compare in vitro and in vivo results for
C15orf57 and MAP2K2 as additional examples of similar sized processing products. Molecular masses of co-migrating marker proteins are
indicated. Note that the α-Pro Western blot result shown for CIAPIN1-HA is extracted from the Western blot shown in Ac. See Additional file 2:
Figure S3 for loading controls as well as more examples of proteins processed by HML-2 Pro in vivo. C. Graphical depictions of candidate
proteins and predictions of processing products as observed when co-expressing candidate proteins and HML-2 Pro-wt in vivo. Numbers of
amino acids and corresponding molecular mass (kDa) are indicated by scales at the top and by the length of lines for each protein. Positions of
cleavage sites, as identified by TAILS experiments at pH 5.5 and pH 7, are indicated by triangles for each protein. Dashed lines indicate molecular
masses of processing products and take into account whether the candidate protein was expressed with an N-terminal or a C-terminal epitope
tag. Note the overlap between predictions and molecular masses of processing products observed in vivo
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Gag protein was furthermore demonstrated in GCT cell
lines and tissue samples (for instance, see [10, 22, 23]).
HML-2 Pro appears to become activated, and is thus
present in cells, independent of budding of retroviral par-
ticles (see the Background section and below). The cellular
consequences of expression of active HML-2 Pro are cur-
rently unknown. The disease relevance of HML-2 Pro is
therefore unknown as well.
We employed a recently developed strategy, TAILS,
for identification of human cellular proteins that are po-
tential substrates of HML-2 Pro using purified HML-2
Pro and the proteome of HeLa cells as a model system.
Our analysis identified a surprisingly high number—at
least in the hundreds—of human proteins as potential
substrates. A different positional proteomics approach
recently identified more than 120 human proteins as
processed by HIV-1 Pro in vitro [30]. Our experimental
approach can be expected to be more sensitive and to
thus identify more proteins than the approach employed
in that study. Interestingly, 57 proteins identified in our
study were also identified in that study [30] likely
because of overall similar specificity profiles of HIV-1
and HML-2 Pro [47]. Methodologically our study com-
prised a broad TAILS approach followed by in vitro ex-
periments and experiments in cultured cells of selected
proteins. This study is a valuable example of this method
combination for providing insight into potential sub-
strates of yet under-investigated proteases.
The number of human proteins processed by HML-2
Pro in vivo is currently difficult to estimate with cer-
tainty. The two TAILS experiments at pH 5.5 identified
approximately 4300 and 2600 cleavage events with at
least 2-fold enrichment of a cleavage event of which 809
different human proteins were common to both experi-
ments. Although HML-2 Pro displayed overall lower ac-
tivity at pH 7, we still identified 500 to 1000 cleavage
events with greater than 1.5-fold enrichment involving
154 different human proteins cleaved in both pH 7
experiments.
Furthermore, we verified processing by HML-2 Pro for
9 out of 14 (65%) human proteins in vitro. The great
majority of the different human proteins examined in
Fig. 7 Multiple alignment of amino acid sequences of Proteases potentially encoded by HERV-K(HML-2) loci. Because HML-2 Pro is
translated via a ribosomal frameshift from the Gag ORF only HML-2 Pro sequences that also harbor a full-length Gag ORF are included.
Note that other HML-2 loci may also encode protease in the case of translation bypassing Gag-Pro frameshifts. The HML-2 Pro ORF also
encodes an upstream dUTPase. The C-terminal “last” dUTPase motif is included in the multiple alignment. Also indicated are a previously
reported N-terminal auto-processing site for HML-2 Pro [44], and DTG, FLAP and GRDLL motifs conserved in retroviral aspartyl proteases.
Note the early stop codons in two sequences that partially or entirely remove the GRDLL region. The HML-2 locus designations used
here are a combination of two established naming systems; the first based on the location of HML-2 loci in chromosomal bands [58]
and the second based on HUGO Gene Nomenclature Committee (HGNC)-approved designations of transcribed HML-2 loci [59]. HERV-
K113 and the three bottom-most sequences are HML-2 sequences not present in the human reference genome [2, 60]. Also note that
locus chr3q27.2_ERVK-11 harbors a fused Gag-Pro ORF that extends approximately 700 aa in the N-terminal direction. Locus 7p22.1_ERVK-
6 represents the protease sequence used for in vitro and in vivo experiments in this study
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vivo also showed evidence of processing by HML-2 Pro.
Our selection of candidate proteins for in vitro testing
involved a filter for certain amino acids in positions P1
and P1’ of observed cleavage sites, and a specific mo-
lecular mass range due to technical limitations of the ex-
perimental in vitro transcription/translation system used
for verification. Even when assuming favored amino
acids in positions P1 and P1’ to be required for cleavage
by HML-2 Pro, one still has to consider several hundred
human proteins as potentially processed by HML-2 Pro
(see Fig. 3a). Furthermore, our TAILS analyses examined
human proteins expressed in HeLa cells. Preparation of
protein lysates likely involved systematic loss of some
protein species because of inadequate lysis conditions
for those proteins, thus very likely resulting in an incom-
plete sampling of the HeLa proteome. Our analysis likely
also missed human proteins expressed at very low levels,
or not at all, in HeLa cells. A recent study of NCI-60 cell
lines identified ~ 5600 human proteins as the core (can-
cer) proteome, another ~ 5000 proteins showing a more
distinct expression pattern between tissues, and ~ 2000
proteins to be cell line- or tissue-specific and not part of
the core proteome [61]. Therefore, TAILS experiments
utilizing cell lines other than HeLa can be expected to
identify a considerable number of additional proteins as
(candidate) substrates of HML-2 Pro. We therefore
hypothesize that even more human proteins than ob-
served in our experiments are potential substrates of
HML-2 Pro.
We verified processing by co-expressed HML-2 Pro
for about two-thirds of selected candidate proteins in
vitro and the great majority in vivo. For the latter,
levels of processing ranged from slight to complete
reduction of full-length candidate protein, sometimes
accompanied by (more or less) stable presumed pro-
cessing products. We conclude that observed reduc-
tion of full-length candidate proteins was not due to
cell death (potentially apoptosis, see the Background
section) triggered by HML-2 Pro and activation of
caspases that then process candidate proteins. FACS
analysis indicated that the majority of transfected cells
were still alive at up to 48 h. Therefore, expressing
HML-2 Pro does not inevitably cause cell death. Fur-
thermore, apoptosis triggered by Staurosporin neither
reduced amounts of full-length candidate protein nor
generated smaller processing products, as is the case
when expressing HML-2 Pro. It was furthermore re-
ported previously that an HA-tag can be cleaved by
caspase-3 and -7, causing loss of immunoreactivity for
HA-tagged proteins [62]. We ruled out the possibility
that observed loss of HA-tagged candidate proteins in
our experiments is due to such HA-tag processing.
First, our in vitro experiments demonstrated process-
ing of candidate proteins by HML-2 Pro, the
specificity of which was further demonstrated by re-
duced processing in the presence of Pepstatin A. Sec-
ond, reduced levels of full-length protein were also
observed for candidate proteins carrying epitope-tags
other than HA. Third, FACS data show that the ma-
jority of HML-2 Pro expressing cells are still alive
after > 30 h, thus apoptosis was not triggered in those
cells. Fourth, induction of apoptosis by Staurosporin,
together with activation of caspases (− 3 and − 7), did
not reduce amounts of HA-tagged full-length candi-
date protein. Fifth, while cell death observed for HIV
Pro was described as apoptosis [38, 63], the specific
mechanism through which HML-2 Pro-expressing
cells die remains to be investigated. Our findings in-
dicate that caspase-3 is present at only low amounts
in HML-2-Pro-expressing cells (not shown).
Our findings strongly argue for HML-2 Pro being en-
zymatically active in vivo and further corroborate pro-
cessing of human proteins by HML-2 Pro in TAILS
experiments at pH 7. There is additional evidence for
HML-2 Pro being enzymatically active in vivo as indi-
cated, for instance, by processing of HML-2 Gag protein
in vivo (see above). HIV-1 Pro has been detected in
membranes, mitochondria and cytoplasm, and was also
shown to be active in the cytoplasm [34, 63]. Our ana-
lysis identified numbers of putative cleaved human pro-
teins that localize to cytosol, membrane, mitochondria,
and other organelles, based on GO-terms. We found
EGFP-tagged mutant HML-2 Pro, that is unable to self-
process from the EGFP-tag, to localize strongly to the
nucleus, as well as in the cytoplasm of U2OS osteosar-
coma cells and HEK293T cells when examined by fluor-
escence microscopy (Additional file 2: Figure S5). Likely,
HML-2 Pro also localizes to the cytosol in cell types
other than U2OS and HEK293T and thus could process
proteins localizing to, or trafficking through, the cytosol.
Whether HML-2 Pro also localizes to, and is active in,
other cellular compartments remains to be investigated.
HML-2 Pro likely would be enzymatically most active in
compartments such as secretory granules, late endo-
somes and lysosomes for which pH 4.7 to 5.5 has been
reported [48].
Human proteins identified as substrates of HML-2 Pro
participate in a diverse array of cellular processes as
assessed by GO-term analyses [49, 50]. Our GO-term
analyses served to compile biological information on
proteins identified in our proteomics experiments. Ap-
proximately 5 times more cytosolic proteins and 2 times
more nuclear proteins than expected by chance were
identified in TAILS experiments. However, it currently
appears unlikely that HML-2 Pro preferentially processes
respective proteins. Human proteins identified as sub-
strates of HML-2 Pro furthermore considerably overlap
with cancer-relevant genes based on COSMIC
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(Catalogue Of Somatic Mutations In Cancer) [53] and
with Mendelian disease phenotypes as revealed by
OMIM [54] (Additional file 1: Tables S3, S4). HML-2
Pro expression might thus impact cell biology in various
ways and contribute to disease by affecting one or more
cellular processes.
HML-2 Gag-Pro precursor protein, from which Pro
self-processes, is translated via an occasional ribosomal
frameshift between Gag and Pro ORFs. Compared to
Gag, lesser amounts of Pro are thus likely produced in
cells. For the purposes of our validation experiments,
we expressed HML-2 Pro from a subregion of the Pro
ORF from which Pro self-processed. The actual
amounts of enzymatically active Pro in cells and tissues
expressing HML-2 are currently unknown. However,
since HML-2 Pro is an enzyme, a relatively small
amount of active Pro could have a significant impact on
cell biology when expressed over long periods of time.
Preliminary data indicate that HML-2 Pro is detectable
by a rabbit polyclonal anti-HML-2-Pro antibody [19] in
cell lines known to overexpress HERV-K(HML-2)
(Additional file 2: Figure S6). Furthermore, transient
expression of EGFP-Pro-mut (Pro does not self-process
from the precursor, see Fig. 6Ab) in such cell lines re-
sults in processing of the Pro portion. The amount of
such processing can be reduced in the presence of HIV
Pro inhibitor Indinavir (Additional file 2: Figure S6). It
thus can be concluded that active HML-2 Pro that is
present in those cells processes EGFP-Pro-mut.
Without further specific experiments, the cellular
consequences deriving from processing of many human
proteins by HML-2 Pro remain speculative. Our identifi-
cation of proteins as potential substrates for HML-2 Pro
processing lays groundwork for a number of specific
experiments. Disease conditions involving known or
suspected HERV-K(HML-2) misregulation or upregula-
tion should be of greatest interest, including, for
example, some cancers and amyotrophic lateral sclerosis
[7, 64]. To the best of our knowledge, a functional role
for HML-2 Pro in such diseases has not yet been
explored.
Expression of HML-2 Pro in disease conditions will de-
pend on which HERV-K(HML-2) loci are transcribed as
only a subset of HML-2 loci appears capable of producing
active protease. Our analysis indicated 6 currently known
reference and 1 non-reference HML-2 sequences poten-
tially capable of producing active protease. Alleles affect-
ing Gag and Pro ORFs were previously shown for locus
7p22.1_ERVK-6 [65], thus only certain alleles of that locus
would encode active protease. Hitherto unidentified alleles
of some other HML-2 loci likewise may possess protease-
coding capacity. It is also conceivable that some Pro ORFs
are translated without Gag-Pro ORF ribosomal frameshifts
or through translational starts within C-terminal Gag ORF
portions. Frameshift-causing pseudoknot RNA structures
may also influence protease-coding capacity of HML-2
loci. In any case, consideration of HML-2 Pro in a particu-
lar disease should include identification of HML-2 loci ac-
tually transcribed along with their protease coding
capability. For instance, Pro-encoding HML-2 loci with a
Gag ORF, specifically loci 3q27.2_ERVK-11, 5q33.3_
ERVK-10, 6q14.1_ERVK-9, 7p22.1_ERVK-6, and 8p23.1_
ERVK-8 (see Fig. 7), were previously identified as tran-
scribed in GCT tissues and/or the GCT-derived cell line
Tera-1 [66–68]. Loci 5q33.3_ERVK-10 and 7p22.1_ERVK-
6 were identified in the context of amyotrophic lateral
sclerosis, yet factual overexpression of HERV-K(HML-2)
in ALS is currently debated [69–72].
We further note that our findings may also have
implications for better understanding biological con-
sequences of certain non-human endogenous ret-
roviruses. For instance, endogenization of Koala
endogenous retrovirus (KoRV) in Koalas (Phascolarctos
cinereus) is ongoing, and KoRV-positive animals de-
velop serious, life-threatening diseases, in particular
malignant neoplasias [73]. The mechanism(s) of KoRV
viral pathogenesis is poorly understood. One might
hypothesize that disease-relevant Koala cellular proteins
are processed by KoRV-encoded protease thus contrib-
uting to disease development.
Taken together, our findings for HERV-K(HML-2) Pro
call for further experiments to better understand the
relevance of endogenous retrovirus-encoded protease in
health and disease in human and other species.
Conclusions
Retroviral proteases are known to process cellular
proteins. While functionally less relevant in the case
of expression of exogenous retroviruses, constitutive ex-
pression of protease encoded by an endogenous retrovirus
is potentially more consequential if processing of cellular
proteins affects cell physiology. Employing specialized pro-
teomics technologies followed by additional experimental
verification, we suggest that retroviral protease of disease-
associated human endogenous retrovirus HERV-K(HML-2)
processes numerous cellular proteins in vitro and in vivo,
with many of those proteins known to be disease-relevant.
Deregulated transcription of HERV-K(HML-2), as reported
for various human diseases, could result in expression of
HERV-K(HML-2) Protease and consequent processing of
various cellular proteins with unknown physiological conse-
quences and disease relevance. Our study provides an ex-
tensive list of human proteins potentially deserving further
specialized investigations, especially relating to diseases
characterized by deregulated HERV-K(HML-2) transcrip-
tion. Disease-relevance of endogenous retrovirus-encoded
protease may also be considered in non-human species.
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Methods
Plasmid constructs for prokaryotic and eukaryotic
protease expression
We generated plasmid constructs for prokaryotic expres-
sion of HERV-K(HML-2) protease (Pro). The coding re-
gion, including flanking sequence regions and self-
processing sites of enzymatically active HERV-K(HML-
2) Pro, as encoded by the previously described HERV-
K(HML-2.HOM) provirus (nt 3277–3769; GenBank acc.
no. AF074086.2) [24], was cloned in-frame into pET11d
prokaryotic expression vector (Novagen). To do so, the
particular region was amplified by PCR from a HERV-
K(HML-2.HOM) provirus previously cloned in pBlue-
script [24]. The forward PCR primer added an NheI site
and the reverse primer added a stop codon and a BamHI
site to the PCR product. The PCR product was sub-
cloned into pGEM T-Easy vector (Promega). The insert
was released by an NheI/BamHI digest and cloned in-
frame into NheI/BamHI-digested pET11d plasmid
(Novagen) giving rise to pET11dPro.
For eukaryotic Pro expression, nt 3415–3946 of
HERV-K(HML-2.HOM) were amplified by PCR, with
the forward primer adding a BamHI site, a spacer and a
Kozak consensus sequence and the reverse primer add-
ing a BamHI site. The PCR product was likewise sub-
cloned into pGEM T-Easy vector, followed by release of
the insert by a BamHI digest and cloning into a BamHI-
digested phCMV eukaryotic expression vector, giving
rise to phCMV-Pro-wt.
For the eukaryotic expression of EGFP-pro fusion pro-
tein nt 3415–3946 of HERV-K(HML-2.HOM) were
amplified by PCR, with both forward and reverse
primers adding a BamHI site each. The PCR product
was subcloned into pGEM T-Easy vector, followed by
release using BamHI and cloning into BamHI-digested
pEGFP-C1 in frame with the EGFP ORF, giving rise to
pEGFP-Pro-wt.
Note that the HERV-K(HML-2.HOM) Pro region used
for generation of expression vectors included a known
N-terminal auto-processing site [20], thus allowing for
release of active HERV-K(HML-2.HOM) Pro from a pre-
cursor protein, e.g. EGFP-Pro.
Following the cloning strategies used for the design of
wild-type Pro containing-plasmids, we also generated
plasmids containing a mutated protease, specifically
pET11dPro-mut, phCMV-Pro-mut, and pEGFP-Pro-
mut. Enzymatically inactive Pro variants were generated
by PCR using Phusion polymerase (New England Bio-
labs) and wt-Pro in pGEM T-Easy vector as the tem-
plate, followed by re-ligation of PCR products. One of
the two PCR-primers introduced the desired mutation.
Specifically, we generated a mutant with a D→N
change in the conserved DTG motif and, only for the
prokaryotic expression, another mutant with a R→K
change in the GRDLL motif. Both mutants were previ-
ously shown to render HML-2 and HIV-1 protease in-
active [44, 74]. Plasmid constructs were verified by
Sanger sequencing.
Plasmids for eukaryotic expression of epitope-tagged
human cellular proteins presumably processed by HERV-
K(HML-2) pro
Full-length coding sequences for HSP90AA1, CIAPIN1,
C15orf57, MAP2K2 and TUBA1A were obtained from
GE Healthcare/Dharmacon and cloned into pcDNA3
with a human influenza hemagglutinin (HA) tag added
during the cloning procedure. To do so, each full-length
ORF was amplified by PCR. The forward PCR primer
was the same as the one used for generation of PCR
products for in vitro translation of proteins (see above).
The reverse PCR primer added an HA-tag in frame at
the ORF’s 3′ end. The PCR product was cloned into
pGEM T-Easy, released by a NotI digest and cloned into
NotI-digested pcDNA3 vector. Clones were verified by
Sanger sequencing.
Other protein cDNAs of interest were cloned into
pEZYflag (Addgene Plasmid #18700) [75] using LR Clo-
nase II and Gateway technology, and contained an N-
terminal FLAG-epitope tag. Those cloned coding se-
quences were from Ultimate ORF libraries (Thermo
Fisher Scientific/Invitrogen) made available through the
ChemCORE facility at Johns Hopkins University, Balti-
more MD, USA (see Additional file 1: Table S5 for clone
identifiers). Other coding sequences for proteins of
interest were obtained from Addgene: pcDNA3 HA
eIF4GI (1–1599) (plasmid #45640) [76], and pCMV-
Tag2B EDD FLAG-UBR5 (plasmid #37188) [77]. Dr. V.
Dawson, Johns Hopkins University School of Medicine,
kindly provided Myc-STUB1 (CHIP) [78]. HSPA5 cDNA
was obtained from Dr. D.L. George, University of Pennsy-
lavania, and was recloned by PCR in the vector pcDNA6
myc/his B (Invitrogen) with a C-terminal T7-tag.
Cell culture
Human embryonic kidney (HEK) 293 T cells (ATCC, or
The Leibniz Institute DSMZ – German Collection of Mi-
croorganisms and Cell Cultures), human osteosarcoma
U2OS cells (a gift from Dr. N. Kedersha, Harvard Univer-
sity), and human cervical cancer HeLa cells (DSMZ) were
grown in Dulbecco’s modified Eagle’s medium (DMEM),
supplemented with 10% heat inactivated fetal bovine
serum (Sigma-Aldrich, or Merck-Millipore), GlutaMax,
and Pen-Strep (Invitrogen/FisherScientific).
Prokaryotic expression and purification of HERV-K(HML-
2.HOM) protease
Expression and purification of HML-2 Pro followed a pre-
viously described protocol [44] with minor modifications.
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In brief, Escherichia coli BL21(DE3) cells harboring plas-
mid pET11dPro (see above) were inoculated into 100ml
Luria-Bertani (LBAmp) medium supplemented with ampi-
cillin (100 μg/ml) and incubated overnight at 37 °C. 20ml
of the overnight culture were then inoculated into 1 L of
LBAmp medium and incubated at 37 °C until A600 = 0.6 was
reached. Expression of HML-2 Pro was induced by addition
of isopropyl-1-thio-β-D-galactopyranoside (Sigma) at a final
concentration of 0.4mM. After 3 h at 37 °C bacterial cells
were pelleted by centrifugation at 6800 g for 30min at 4 °C.
Cells were resuspended in 50ml of pre-cooled 5× TE buffer
(0.1M Tris/HCl, 5mM EDTA, pH 7.5) and subjected to
sonication (10 × 10 s, 40W) on ice. The cell lysate was cen-
trifuged for 30min at 3600 g and 4 °C and the soluble frac-
tion was discarded. Inclusion bodies were washed twice
with 20ml of 5× TE buffer and then dissolved in 100ml of
8M urea, 0.1M Tris/HCl pH 7.5, 1mM DTT. Refolding of
HML-2 Pro was achieved by dialyzing the solution against
4 L of 20mM PIPES, pH 6.5, 1M NaCl, 1mM DTT, at
4 °C for 3 h and then against 4 L of fresh buffer overnight.
During renaturation, the HML-2 Pro precursor of 18 kDa
completely autoprocessed into the mature 12 kDa form.
The solution was centrifuged for 30min at 6800 g and 4 °C
to eliminate precipitated proteins and then mixed 1:1 with
buffer A (50mM PIPES, pH 6.5, 1M NaCl, 1mM EDTA,
1mM NaK tartrate, 10% [v/v] glycerol). Five ml of Pepstatin
A-agarose (Sigma), pre-washed in H2Odd and then buffer
A, were added and the mixture was incubated overnight at
4 °C with slow agitation and subsequently packed onto a
chromatography column pre-conditioned with Buffer A.
Aliquots from flow-through and two fractions from wash
steps were collected (see below). Bound proteins were
eluted by gravity with Buffer B (0.1M Tris/HCl, pH 8.0, 1
mM NaK tartrate, 10% [v/v] glycerol, 5% [v/v] ethylene gly-
col) collecting 6 elution fractions of 5ml each. The various
purification steps were monitored by SDS-PAGE followed
by Coomassie-staining of PAA-gels. Protease-containing
elution fractions were pooled and concentrated using an
Amicon centrifugal filter (3000 MWCO) to a final volume
of about 2ml. Protease concentration was determined by
DC Protein assay (Biorad) and UV spectrophotometry
using a calculated molar absorption coefficient of 29,115
M− 1 cm− 1 of expressed HML-2 Pro. The protein solution
was aliquoted and stored at − 80 °C.
Optimization of HERV-K(HML-2.HOM) protease activity by
in vitro enzymatic fluorescence assays
We monitored and optimized HERV-K(HML-2.HOM)
Pro activity by varying buffer composition, pH, and Pep-
statin A concentration. A synthetic fluorescent Anthrani-
lyl-Substrate Trifluoroacetate salt, 2-aminobenzoyl-Thr-Ile-
Nle-p-nitro-Phe-Gln-Arg-NH2 (4,030,748, BACHEM), a
known substrate of HIV Pro [46], was dissolved in
DMSO to produce a 1.06 mM stock solution. Purified
HERV-K(HML-2.HOM) mature Pro was diluted in
Buffer B to a final concentration of 4.6 μM (see
above). Protease was then incubated at a final concen-
tration of 460 nM with fluorescent substrate (final
concentration 20 μM, 40 μM for Pepstatin A inhib-
ition experiments) in a final volume of 50 μl. Reac-
tions were monitored at 37 °C by detecting increase
in fluorescent signal for each reaction condition every
4 min for up to 180 min. Fluorescence measurements
were taken in 96-well microplates (Greiner Bio-One
655,087) using a Tecan Infinite m200 spectrophotom-
eter with excitation at 280 nm and emission measured
at 420 nm. The amount of fluorescent product, thus
HML-2 Pro activity, was calculated based on changes
in fluorescence emission.
Preparation of Hela total cell lysate
Human cervical adenocarcinoma (HeLa) cells were cul-
tured at 37 °C and 5% [v/v] CO2 in Dulbecco’s Modified
Eagle’s Medium supplemented with 10% [v/v] heat inac-
tivated fetal calf serum, 50 μg/ml penicillin, and 50 μg/
ml streptomycin. A total of 1.4•108 cells grown to near
confluence in eight 160 cm2 tissue culture flasks were
washed with 1× PBS and detached by trypsinization.
Cells were collected in 20 ml 1× PBS, pelleted for 5 min
at 250 g, resuspended in 0.5 ml of 5 mM MES, pH 6.0
supplemented with protease inhibitors (cOmplete,Mini,
EDTA-free, Roche) at the recommended concentration,
and subjected to lysis by three freeze-thaw cycles. The
protein lysate was centrifuged at 4 °C for 30 min. at 16,
100 g. The supernatant was stored in aliquots at − 80 °C.
Protein concentration was measured using the Biorad
DC Protein Assay Kit.
Incubation of HeLa total cell lysate with purified HERV-
K(HML-2) protease and subsequent TAILS analysis
In a total reaction volume of 2 ml, we incubated 2 mg of
HeLa proteins with purified HML-2 Pro (200 nM final
concentration) in a buffer composed of 0.1 M PIPES, 1
M NaCl, and 2% [v/v] DMSO, pH 5.5 or pH 7. Two rep-
licates were performed. Additional control reactions for
each condition contained Pepstatin A at 200 μM that
was concluded to effectively inhibit HML-2 Pro activity.
All reactions were incubated for 75 min. at 37 °C and
stored at − 80 °C until TAILS analysis (see below).
TAILS was performed essentially as described previously
[42, 43], comparing HML-2 Pro-treated HeLa total cell
lysate to control reactions for the two replicates per-
formed at pH 5.5 and at pH 7. An Easy-LC 1000 coupled
to a Q-Exactive plus mass spectrometer was used for
LC-MS analysis. The mass spectrometry proteomics data
have been deposited to the ProteomeXchange Consor-
tium via the PRIDE [79] partner repository (dataset
identifiers PXD010159 and PXD013296).
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In vitro translation of proteins presumably processed by
HERV-K(HML-2) protease
The coding region of full-length protein was PCR-ampli-
fied from purified plasmid template DNA (see above).
Forward primers were located at the start codon and in-
cluded a 5′ extension consisting of a BamHI restriction
site, a T7 promoter, a spacer and a Kozak consensus se-
quence for translation-initiation (5′-GGATCC|TAATA
CGACTCACTATAGGG|AACAG|CCACCATG [cDNA
candidate protein]-3′). The reverse primers added se-
quence encoding a human influenza hemagglutinin (HA)
epitope tag and a stop codon (5′-TTA|AGCGTAATCTG-
GAACATCGTATGGGTA[cDNA candidate protein]-3′)
at the end to the PCR product’s protein coding sequence.
The standard PCR mix contained primers at a final con-
centration of 0.25 μM, 100 μM dNTP mix, 2.5 U Taq poly-
merase (Sigma), and 5 ng template DNA in a final
reaction volume of 50 μl. PCR cycling conditions were as
follows: 3min. at 94 °C; 30 cycles of 50 s. at 94 °C, 50 s. at
56 °C, 3min at 72 °C; and a final 10min. at 72 °C. PCR
products directly served as template using a TnT T7
Quick Coupled Transcription/Translation System (Promega)
following the manufacturer’s recommendations. Briefly,
2.5 μl of a PCR reaction were added to 22 μl of TNT T7
PCR Quick Master Mix containing either 0.5 μl of HPLC-
purified, translation-grade L-35S-methionine (370MBq, 10
mCi/ml; Hartmann Analytic, Braunschweig, Germany) or
0.5 μl of 1mM “cold” methionine, incubated for 90min. at
30 °C and frozen at − 20 °C immediately afterwards.
Incubation of candidate proteins with purified HERV-
K(HML-2) protease in vitro
In vitro transcribed/translated radioactively or HA-tag-la-
beled candidate protein was incubated with purified HML-
2 Pro to potentially confirm in vitro processing by HML-2
Pro. Briefly, 1 μl of the TNT® T7 in vitro transcription/
translation reaction was incubated with 400 nM purified
HML-2 Pro in a buffer of 1M NaCl, and 0.1M PIPES pH
5.5, for 180min. at 37 °C in a final volume of 16 μl. Control
reactions included Pepstatin A at 400 μM. The entire reac-
tion was subjected to SDS-PAGE (see below).
Co-expression of candidate proteins and HERV-K(HML-2)
protease in HEK293T cells
In the case of Western blots shown in Fig. 6a, b (top) and
Additional file 2: Figure S3 (those with Coomassie staining),
HEK293T cells were seeded at a density of 2•105 cells per
well in a 12-well plate. The following day, cells were trans-
fected with either phCMV-Pro-wt, phCMV-Pro-mut and
phCMV, or pEGFP-Pro-wt, pEGFP-Pro-mut and pEGFP.
Candidate protein cDNAs (HSP90AA1, CIAPIN1,
C15orf57, MAP2K2, TUBA1A) cloned in pcDNA3 vector
were co-transfected. Transfections were performed using
Fugene HD Transfection Reagent (Promega) at a DNA:
Fugene ratio of 1:3. Each plasmid combination was trans-
fected in duplicate in two different wells. Combinations of
plasmids were co-transfected as follows. EGFP-fused
wild-type protease + candidate protein: 0.5 μg pEGFP-
Pro-wt + 0.5 μg pcDNA3-candidate; EGFP-fused mutated
protease + candidate protein: 0.5 μg pEGFP-Pro-mut +
0.5 μg pcDNA3-candidate; GFP-Control: 0.5 μg pEGFP +
0.5 μg pcDNA3-candidate; wild-type protease + candidate
protein: 0.5 μg phCMV-Pro-wt + 0.5 μg pcDNA3-candidate;
mutated Pro + candidate protein: 0.5 μg phCMV-Pro-
mut + 0.5 μg pcDNA3-candidate; Control: 0.5 μg phCMV
+ 0.5 μg pcDNA3-candidate. 24 h post transfection, ~ 0,
8•106 cells each were washed with 1xPBS, trypsinized and
pelleted by centrifugation for 5min. at 300 g in 1xPBS. Cell
pellets were resuspended and lysed in 100 μl of RIPA buffer
(150mM NaCl, 1% [v/v] NP40, 0.5% [w/v] sodium deoxy-
cholate, 0,1% [w/v] SDS, 50mM Tris-HCl pH 8.0 and 5
mM EDTA), supplemented with protease inhibitors
(cOmplete Mini, EDTA-free, Roche) and Pepstatin-A
(Merck Chemicals) at 1 μg/μl final concentration. Insoluble
cell debris was pelleted by centrifugation at ~ 13,000 g for
15min. at 4 °C. Protein concentration was measured using
the DC Protein Assay Kit (Biorad).
In the case of Western blots shown in Fig. 6b (bottom)
and Additional file 2: Figure S3 (those with Ponceau S
staining), HEK293T cells seeded in 6-well plates were
co-transfected with test plasmids together with pcDNA6
myc/his B or pcDNA5 FRT/TO empty vector (Invitro-
gen/Thermo Fisher Scientific), phCMV-Pro-wt, or
phCMV-Pro-mut. After 18 h, MG132 (Millipore-Sigma)
at a final concentration of 10 μM was added and cells
were incubated for an additional 4–5 h. Cells from dupli-
cate wells were pooled and lysed with RIPA Buffer
(Millipore-Sigma) supplemented with Mammalian Prote-
ase Inhibitor Cocktail (Sigma) and 2mM phenylmethyl-
sulfonyl fluoride (PMSF). Note that Protease Inhibitor
Cocktail contains Pepstatin A. Protein lysates were soni-
cated with a Diagenode Bioruptor and centrifuged at
13000 g at 4 °C for 15 min to recover supernatant. Pro-
tein concentrations were determined with the Pierce
BCA Protein Assay Kit (Thermo Fisher Scientific).
SDS-PAGE and detection of labeled proteins
In the case of Western blots shown in Fig. 6a, b (top)
and Additional file 2: Figure S3 (those with Coomassie
staining), between 15 and 20 μg of each total protein
sample, with equal amounts of each protein sample
loaded per candidate protein examined, were subjected
to reducing SDS-PAGE using a Bis-Tris buffer system.
Protein lysates were mixed with 4× NuPAGE LDS Sam-
ple Buffer (Thermo Fisher Scientific) and DTT at 50
mM final concentration, denatured for 15 min. at 65 °C,
and briefly centrifuged. Protein samples were loaded and
separated in 10% or 12% Bis-Tris polyacrylamide gels at
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180 V in XCell SureLock™ Mini-Cells using NuPAGE
MES SDS or MOPS SDS Running Buffer and optional
NuPAGE Antioxidant.
Polyacrylamide gels with radiolabeled proteins were fixed
for 30min. in 50% [v/v] methanol/10% [v/v] acetic acid,
then soaked in distilled water three times for 10min each.
Gels were dried for 2 h at 80 °C under vacuum and subse-
quently exposed to a Storage Phosphor screen (Amersham
Biosciences) at room temperature for 16 h. The screen was
scanned using a Typhoon 9410 scanner (GE Healthcare).
Detection of cold proteins was done by Western blot.
Following SDS-PAGE, proteins were transferred onto
Hybond 0.2 μm PVDF membrane (Amersham/GE Health-
care) using a XCell II™ Blot module and NuPAGE Trans-
fer Buffer in the presence of NuPAGE Antioxidant. Blot
membranes were blocked in 1× TBS, 5% [w/v] nonfat dry
milk for 1 h and incubated overnight at 4 °C with an α-HA
rat monoclonal antibody diluted 1:500 in 1× TBS/5% [w/
v] nonfat dry milk. Detection of proteins of interest
employed antibodies specific for HA-tag, EGFP, and
HML-2 Pro [19]. Secondary antibody incubation was done
using peroxidase-coupled rabbit α-rat IgG (Sigma-Aldrich;
A5795) or goat α-rabbit IgG (Sigma-Aldrich; A0545) each
diluted at 1:5000, for 2 h at room temperature. α-HA rat
monoclonal (clone 3F10) and rabbit α-rat antibodies were
generously provided by Friedrich Grässer, Institute of
Virology, University of Saarland. Signal detection was
performed using SignalFire™ Elite ECL Reagent (Cell
Signaling Technology) and Chemidoc™ Imaging System
(Bio-Rad). Image analysis utilized ImageLab 5.2.1 software
(Bio-Rad). Loading of equal protein amounts was verified
by staining blot membranes with Coomassie Brilliant Blue
after the ECL procedure.
In the case of Western blots shown in Fig. 6b (bottom)
and Additional file 2: Figure S3 (those with PonceauS
staining), 35 μg of total protein resuspended in 3× SDS
loading buffer (187.5mM Tris-HCl (pH 7.5), 6% [w/v]
SDS, 30% [v/v] glycerol, 0.03% [w/v] bromophenol blue,
2% [v/v] β-mercaptoethanol) was subjected to reducing
SDS-PAGE in XCell SureLock™ Mini-Cells with 4–12%
NuPAGE Bis-Tris polyacrylamide gels and MOPS SDS
Running Buffer. Proteins were blotted as above, except,
PVDF membranes were blocked in 1× PBS, 5% [w/v] non-
fat dry milk for 1 h and incubated overnight at 4 °C with
primary antibodies for epitope tags or endogenous pro-
teins in 1× PBS/2.5% [w/v] nonfat dry milk/0.5% Tween
20. Antibodies used included mouse α-T7-Tag (Novagen,
diluted 1:4000), and rabbit α-DYKDDDDK (FLAG)-tag
(clone D6W5B), mouse α-HA-tag (clone 6E2), rabbit α-
Myc-tag (clone 71D10), and rabbit α-HSP90 (clone
C45G5) (all from Cell Signaling Technology, diluted 1:
1500), and donkey horseradish peroxidase-conjugated sec-
ondary antibodies from Jackson ImmunoResearch Labora-
tories (diluted 1:10,000). Signal detection was performed
using SuperSignal West Pico PLUS Chemiluminescent
Substrate (Thermo Fisher Scientific) and Hyperfilm ECL
(Sigma Aldrich). Loading of equal protein amounts was
verified by Ponceau S staining of membranes after the
ECL procedure.
Identification of HERV-K(HML-2) loci potentially encoding
protease
Reference and non-reference HERV-K(HML-2) locus se-
quences were analyzed for presence of pro ORFs. HML-
2 pro is translated via a ribosomal frameshift between
the HML-2 gag and pro ORFs. We therefore also ana-
lyzed for presence of a gag ORF in respective HML-2 se-
quences. Pro ORFs of HML-2 loci fulfilling criteria were
translated in silico, multiply aligned, and further ana-
lyzed for presence of catalytic motifs conserved in retro-
viral aspartate proteases
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